Get the Most Out of OCT in Your Practice - Review of Optometry
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Optical coherence tomography (OCT) has transformed the diagnosis and management of retinal, optic nerve and anterior segment diseases. It is incorporated in evidence-based practice guidelines and pivotal clinical trials as the reference imaging modality for diagnosis, treatment decisions and monitoring. Spectral-domain OCT (SD-OCT) instruments have remained the mainstay office-based platform taking over the previous time-domain OCT (TD-OCT) option. Advancements in OCT technology have expanded its clinical applications, enabling imaging from the cornea to the peripheral retina. Clinicians have several commercially available spectral-domain (SD) OCT models to choose from. For this article, four prominent ones will be described: Cirrus HD SD-OCT 5000 (Carl Zeiss Meditec), 3D OCT-1 Maestro2 (Topcon Healthcare), Spectralis SD-OCT (Heidelberg Engineering) and Optovue iVue80 (Visionix). This article outlines the basics of OCT imaging, the newest model updates, a guided data analysis of the different instruments’ metrics and how to interpret various measurements using each model. Enhanced Depth Imaging (EDI-OCT) This technology positions deeper structures near the zero-delay line.
This article is an excerpt. To read the full content, visit the original source. Review of Optometry
Related articles
European Medical Journal | HIV linked to early signs of heart dysfunction - European AIDS Treatment Group
Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress
Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!